In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 276 to 300 of 344

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG ID6454	Technology appraisal guidance	TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]	Technology appraisal guidance	TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]	Technology appraisal guidance	TBC
Seladelpar for previously treated primary biliary cholangitis [ID6429]	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]	Technology appraisal guidance	TBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]	Technology appraisal guidance	14 May 2026
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]	Technology appraisal guidance	12 August 2026
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]	Technology appraisal guidance	TBC
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542	Technology appraisal guidance	10 February 2027
Sipavibart for preventing COVID 19 [ID6282]	Technology appraisal guidance	TBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]	Technology appraisal guidance	TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]	Technology appraisal guidance	TBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]	Technology appraisal guidance	11 March 2026
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]	Technology appraisal guidance	TBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632	Technology appraisal guidance	TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]	Technology appraisal guidance	TBC
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]	Technology appraisal guidance	21 April 2021
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]	Technology appraisal guidance	TBC
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]	Technology appraisal guidance	TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]	Technology appraisal guidance	TBC
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]	Technology appraisal guidance	10 June 2027

Results per page

10
25
50
All